Perseus Proteomics Presents PPMX-T003 Phase I Trial Results at ASH Meeting

MT Newswires Live

2024/12/11

Perseus Proteomics (TYO:4882) presented phase I results of its anti-TfR1 antibody, PPMX-T003, at the 66th ASH Annual Meeting, according to a Tuesday filing on the Tokyo Stock Exchange.

The trial, conducted with six polycythemia vera patients, showed no serious adverse effects and demonstrated efficacy, with five patients completing 12 weeks without phlebotomy, the filing said.

The company is also developing other antibody therapies for cancer.

Price (JPY): $742.00, Change: $+22, Percent Change: +3.06%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2490737460"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490737460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490737460?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490737460","market":"sh","top_or_hot":-1,"title":"Perseus Proteomics Presents PPMX-T003 Phase I Trial Results at ASH Meeting","media":"MT Newswires Live","content":"<html><body><p> Perseus Proteomics (TYO:4882) presented phase I results of its anti-TfR1 antibody, PPMX-T003, at the 66th ASH Annual Meeting, according to a Tuesday filing on the Tokyo Stock Exchange.</p><p>The trial, conducted with six polycythemia vera patients, showed no serious adverse effects and demonstrated efficacy, with five patients completing 12 weeks without phlebotomy, the filing said.</p><p>The company is also developing other antibody therapies for cancer.</p><p>Price (JPY): $742.00, Change: $+22, Percent Change: +3.06%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Perseus Proteomics Presents PPMX-T003 Phase I Trial Results at ASH Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPerseus Proteomics Presents PPMX-T003 Phase I Trial Results at ASH Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-11 07:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Perseus Proteomics (TYO:4882) presented phase I results of its anti-TfR1 antibody, PPMX-T003, at the 66th ASH Annual Meeting, according to a Tuesday filing on the Tokyo Stock Exchange.</p><p>The trial, conducted with six polycythemia vera patients, showed no serious adverse effects and demonstrated efficacy, with five patients completing 12 weeks without phlebotomy, the filing said.</p><p>The company is also developing other antibody therapies for cancer.</p><p>Price (JPY): $742.00, Change: $+22, Percent Change: +3.06%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2463526074.USD","symbol_name":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490737460","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490737460","pubTimestamp":1733873842,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Perseus Proteomics  presented phase I results of its anti-TfR1 antibody, PPMX-T003, at the 66th ASH Annual Meeting, according to a Tuesday filing on the Tokyo Stock Exchange.The trial, conducted with six polycythemia vera patients, showed no serious adverse effects and demonstrated efficacy, with five patients completing 12 weeks without phlebotomy, the filing said.The company is also developing other antibody therapies for cancer.Price : $742.00, Change: $+22, Percent Change: +3.06%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK4109":"特种化学制品","ASH":"Ashland"},"translate_title":"Perseus Proteomics在ASH会议上展示PPMX-T003 I期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASH":1},"content_text":"Perseus Proteomics (TYO:4882) presented phase I results of its anti-TfR1 antibody, PPMX-T003, at the 66th ASH Annual Meeting, according to a Tuesday filing on the Tokyo Stock Exchange.The trial, conducted with six polycythemia vera patients, showed no serious adverse effects and demonstrated efficacy, with five patients completing 12 weeks without phlebotomy, the filing said.The company is also developing other antibody therapies for cancer.Price (JPY): $742.00, Change: $+22, Percent Change: +3.06%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}